Genelux Insider Sales: Thomas John’s Gradual Divestment Signals Strategic Shift
Insider sales at Genelux reveal a cautious divest‑strategy amid a volatile biopharma market. Understand how Thomas John’s gradual selling and broader exec moves hint at future value, reimbursement plans, and tech adoption—key insights for investors …
4 minutes to read